IL	B:C1706289
-	I:C1706289
27	I:C1706289
Is	O
Essential	O
for	O
Suppression	O
of	O
Experimental	O
Allergic	O
Asthma	I:C0155877
by	O
the	O
TLR7	O
/	O
8	O
Agonist	O
R848	O
(	O
Resiquimod	O
)	O
Different	O
models	O
of	I:C0684309
experimental	I:C0684309
allergic	O
asthma	I:C0155877
have	O
shown	O
that	O
the	O
TLR7	O
/	O
8	O
agonist	O
resiquimod	O
(	O
R848	O
)	O
is	O
a	O
potential	O
inhibitor	O
of	O
type	O
2	I:C0242633
helper	I:C0242633
cell	I:C0242633
-	O
driven	O
inflammatory	O
responses	I:C1155266
.	O

IL	O
-	I:C1706289
27	I:C1706289
Is	O
Essential	O
for	O
Suppression	B:C0021079
of	O
Experimental	O
Allergic	O
Asthma	I:C0155877
by	O
the	O
TLR7	O
/	O
8	O
Agonist	O
R848	O
(	O
Resiquimod	O
)	O
Different	O
models	O
of	I:C0684309
experimental	I:C0684309
allergic	O
asthma	I:C0155877
have	O
shown	O
that	O
the	O
TLR7	O
/	O
8	O
agonist	O
resiquimod	O
(	O
R848	O
)	O
is	O
a	O
potential	O
inhibitor	O
of	O
type	O
2	I:C0242633
helper	I:C0242633
cell	I:C0242633
-	O
driven	O
inflammatory	O
responses	I:C1155266
.	O

IL	O
-	I:C1706289
27	I:C1706289
Is	O
Essential	O
for	O
Suppression	O
of	O
Experimental	O
Allergic	B:C0155877
Asthma	I:C0155877
by	O
the	O
TLR7	O
/	O
8	O
Agonist	O
R848	O
(	O
Resiquimod	O
)	O
Different	O
models	O
of	I:C0684309
experimental	I:C0684309
allergic	O
asthma	I:C0155877
have	O
shown	O
that	O
the	O
TLR7	O
/	O
8	O
agonist	O
resiquimod	O
(	O
R848	O
)	O
is	O
a	O
potential	O
inhibitor	O
of	O
type	O
2	I:C0242633
helper	I:C0242633
cell	I:C0242633
-	O
driven	O
inflammatory	O
responses	I:C1155266
.	O

IL	O
-	I:C1706289
27	I:C1706289
Is	O
Essential	O
for	O
Suppression	O
of	O
Experimental	O
Allergic	O
Asthma	I:C0155877
by	O
the	O
TLR7	B:C1579758
/	O
8	O
Agonist	O
R848	O
(	O
Resiquimod	O
)	O
Different	O
models	O
of	I:C0684309
experimental	I:C0684309
allergic	O
asthma	I:C0155877
have	O
shown	O
that	O
the	O
TLR7	O
/	O
8	O
agonist	O
resiquimod	O
(	O
R848	O
)	O
is	O
a	O
potential	O
inhibitor	O
of	O
type	O
2	I:C0242633
helper	I:C0242633
cell	I:C0242633
-	O
driven	O
inflammatory	O
responses	I:C1155266
.	O

IL	O
-	I:C1706289
27	I:C1706289
Is	O
Essential	O
for	O
Suppression	O
of	O
Experimental	O
Allergic	O
Asthma	I:C0155877
by	O
the	O
TLR7	O
/	O
8	B:C1579755
Agonist	O
R848	O
(	O
Resiquimod	O
)	O
Different	O
models	O
of	I:C0684309
experimental	I:C0684309
allergic	O
asthma	I:C0155877
have	O
shown	O
that	O
the	O
TLR7	O
/	O
8	O
agonist	O
resiquimod	O
(	O
R848	O
)	O
is	O
a	O
potential	O
inhibitor	O
of	O
type	O
2	I:C0242633
helper	I:C0242633
cell	I:C0242633
-	O
driven	O
inflammatory	O
responses	I:C1155266
.	O

IL	O
-	I:C1706289
27	I:C1706289
Is	O
Essential	O
for	O
Suppression	O
of	O
Experimental	O
Allergic	O
Asthma	I:C0155877
by	O
the	O
TLR7	O
/	O
8	O
Agonist	B:C2987634
R848	O
(	O
Resiquimod	O
)	O
Different	O
models	O
of	I:C0684309
experimental	I:C0684309
allergic	O
asthma	I:C0155877
have	O
shown	O
that	O
the	O
TLR7	O
/	O
8	O
agonist	O
resiquimod	O
(	O
R848	O
)	O
is	O
a	O
potential	O
inhibitor	O
of	O
type	O
2	I:C0242633
helper	I:C0242633
cell	I:C0242633
-	O
driven	O
inflammatory	O
responses	I:C1155266
.	O

IL	O
-	I:C1706289
27	I:C1706289
Is	O
Essential	O
for	O
Suppression	O
of	O
Experimental	O
Allergic	O
Asthma	I:C0155877
by	O
the	O
TLR7	O
/	O
8	O
Agonist	O
R848	B:C3642356
(	O
Resiquimod	O
)	O
Different	O
models	O
of	I:C0684309
experimental	I:C0684309
allergic	O
asthma	I:C0155877
have	O
shown	O
that	O
the	O
TLR7	O
/	O
8	O
agonist	O
resiquimod	O
(	O
R848	O
)	O
is	O
a	O
potential	O
inhibitor	O
of	O
type	O
2	I:C0242633
helper	I:C0242633
cell	I:C0242633
-	O
driven	O
inflammatory	O
responses	I:C1155266
.	O

IL	O
-	I:C1706289
27	I:C1706289
Is	O
Essential	O
for	O
Suppression	O
of	O
Experimental	O
Allergic	O
Asthma	I:C0155877
by	O
the	O
TLR7	O
/	O
8	O
Agonist	O
R848	O
(	O
Resiquimod	B:C0965594
)	O
Different	O
models	O
of	I:C0684309
experimental	I:C0684309
allergic	O
asthma	I:C0155877
have	O
shown	O
that	O
the	O
TLR7	O
/	O
8	O
agonist	O
resiquimod	O
(	O
R848	O
)	O
is	O
a	O
potential	O
inhibitor	O
of	O
type	O
2	I:C0242633
helper	I:C0242633
cell	I:C0242633
-	O
driven	O
inflammatory	O
responses	I:C1155266
.	O

IL	O
-	I:C1706289
27	I:C1706289
Is	O
Essential	O
for	O
Suppression	O
of	O
Experimental	O
Allergic	O
Asthma	I:C0155877
by	O
the	O
TLR7	O
/	O
8	O
Agonist	O
R848	O
(	O
Resiquimod	O
)	O
Different	O
models	B:C0684309
of	I:C0684309
experimental	I:C0684309
allergic	O
asthma	I:C0155877
have	O
shown	O
that	O
the	O
TLR7	O
/	O
8	O
agonist	O
resiquimod	O
(	O
R848	O
)	O
is	O
a	O
potential	O
inhibitor	O
of	O
type	O
2	I:C0242633
helper	I:C0242633
cell	I:C0242633
-	O
driven	O
inflammatory	O
responses	I:C1155266
.	O

IL	O
-	I:C1706289
27	I:C1706289
Is	O
Essential	O
for	O
Suppression	O
of	O
Experimental	O
Allergic	O
Asthma	I:C0155877
by	O
the	O
TLR7	O
/	O
8	O
Agonist	O
R848	O
(	O
Resiquimod	O
)	O
Different	O
models	O
of	I:C0684309
experimental	I:C0684309
allergic	B:C0155877
asthma	I:C0155877
have	O
shown	O
that	O
the	O
TLR7	O
/	O
8	O
agonist	O
resiquimod	O
(	O
R848	O
)	O
is	O
a	O
potential	O
inhibitor	O
of	O
type	O
2	I:C0242633
helper	I:C0242633
cell	I:C0242633
-	O
driven	O
inflammatory	O
responses	I:C1155266
.	O

IL	O
-	I:C1706289
27	I:C1706289
Is	O
Essential	O
for	O
Suppression	O
of	O
Experimental	O
Allergic	O
Asthma	I:C0155877
by	O
the	O
TLR7	O
/	O
8	O
Agonist	O
R848	O
(	O
Resiquimod	O
)	O
Different	O
models	O
of	I:C0684309
experimental	I:C0684309
allergic	O
asthma	I:C0155877
have	O
shown	O
that	O
the	O
TLR7	B:C1579758
/	O
8	O
agonist	O
resiquimod	O
(	O
R848	O
)	O
is	O
a	O
potential	O
inhibitor	O
of	O
type	O
2	I:C0242633
helper	I:C0242633
cell	I:C0242633
-	O
driven	O
inflammatory	O
responses	I:C1155266
.	O

IL	O
-	I:C1706289
27	I:C1706289
Is	O
Essential	O
for	O
Suppression	O
of	O
Experimental	O
Allergic	O
Asthma	I:C0155877
by	O
the	O
TLR7	O
/	O
8	O
Agonist	O
R848	O
(	O
Resiquimod	O
)	O
Different	O
models	O
of	I:C0684309
experimental	I:C0684309
allergic	O
asthma	I:C0155877
have	O
shown	O
that	O
the	O
TLR7	O
/	O
8	B:C1579755
agonist	O
resiquimod	O
(	O
R848	O
)	O
is	O
a	O
potential	O
inhibitor	O
of	O
type	O
2	I:C0242633
helper	I:C0242633
cell	I:C0242633
-	O
driven	O
inflammatory	O
responses	I:C1155266
.	O

IL	O
-	I:C1706289
27	I:C1706289
Is	O
Essential	O
for	O
Suppression	O
of	O
Experimental	O
Allergic	O
Asthma	I:C0155877
by	O
the	O
TLR7	O
/	O
8	O
Agonist	O
R848	O
(	O
Resiquimod	O
)	O
Different	O
models	O
of	I:C0684309
experimental	I:C0684309
allergic	O
asthma	I:C0155877
have	O
shown	O
that	O
the	O
TLR7	O
/	O
8	O
agonist	B:C2987634
resiquimod	O
(	O
R848	O
)	O
is	O
a	O
potential	O
inhibitor	O
of	O
type	O
2	I:C0242633
helper	I:C0242633
cell	I:C0242633
-	O
driven	O
inflammatory	O
responses	I:C1155266
.	O

IL	O
-	I:C1706289
27	I:C1706289
Is	O
Essential	O
for	O
Suppression	O
of	O
Experimental	O
Allergic	O
Asthma	I:C0155877
by	O
the	O
TLR7	O
/	O
8	O
Agonist	O
R848	O
(	O
Resiquimod	O
)	O
Different	O
models	O
of	I:C0684309
experimental	I:C0684309
allergic	O
asthma	I:C0155877
have	O
shown	O
that	O
the	O
TLR7	O
/	O
8	O
agonist	O
resiquimod	B:C0965594
(	O
R848	O
)	O
is	O
a	O
potential	O
inhibitor	O
of	O
type	O
2	I:C0242633
helper	I:C0242633
cell	I:C0242633
-	O
driven	O
inflammatory	O
responses	I:C1155266
.	O

IL	O
-	I:C1706289
27	I:C1706289
Is	O
Essential	O
for	O
Suppression	O
of	O
Experimental	O
Allergic	O
Asthma	I:C0155877
by	O
the	O
TLR7	O
/	O
8	O
Agonist	O
R848	O
(	O
Resiquimod	O
)	O
Different	O
models	O
of	I:C0684309
experimental	I:C0684309
allergic	O
asthma	I:C0155877
have	O
shown	O
that	O
the	O
TLR7	O
/	O
8	O
agonist	O
resiquimod	O
(	O
R848	B:C3642356
)	O
is	O
a	O
potential	O
inhibitor	O
of	O
type	O
2	I:C0242633
helper	I:C0242633
cell	I:C0242633
-	O
driven	O
inflammatory	O
responses	I:C1155266
.	O

IL	O
-	I:C1706289
27	I:C1706289
Is	O
Essential	O
for	O
Suppression	O
of	O
Experimental	O
Allergic	O
Asthma	I:C0155877
by	O
the	O
TLR7	O
/	O
8	O
Agonist	O
R848	O
(	O
Resiquimod	O
)	O
Different	O
models	O
of	I:C0684309
experimental	I:C0684309
allergic	O
asthma	I:C0155877
have	O
shown	O
that	O
the	O
TLR7	O
/	O
8	O
agonist	O
resiquimod	O
(	O
R848	O
)	O
is	O
a	O
potential	O
inhibitor	O
of	O
type	B:C0242633
2	I:C0242633
helper	I:C0242633
cell	I:C0242633
-	O
driven	O
inflammatory	O
responses	I:C1155266
.	O

IL	O
-	I:C1706289
27	I:C1706289
Is	O
Essential	O
for	O
Suppression	O
of	O
Experimental	O
Allergic	O
Asthma	I:C0155877
by	O
the	O
TLR7	O
/	O
8	O
Agonist	O
R848	O
(	O
Resiquimod	O
)	O
Different	O
models	O
of	I:C0684309
experimental	I:C0684309
allergic	O
asthma	I:C0155877
have	O
shown	O
that	O
the	O
TLR7	O
/	O
8	O
agonist	O
resiquimod	O
(	O
R848	O
)	O
is	O
a	O
potential	O
inhibitor	O
of	O
type	O
2	I:C0242633
helper	I:C0242633
cell	I:C0242633
-	O
driven	O
inflammatory	B:C1155266
responses	I:C1155266
.	O

However	O
,	O
the	O
mechanisms	O
mediating	O
its	O
therapeutic	B:C1527144
effects	I:C1527144
are	O
not	O
fully	O
understood	O
.	O

Using	O
a	O
model	B:C0684309
of	I:C0684309
experimental	I:C0684309
allergic	O
asthma	I:C0155877
,	O
we	O
show	O
that	O
induction	O
of	O
IL	O
-	I:C1706289
27	I:C1706289
by	O
R848	O
is	O
critical	O
for	O
the	O
observed	O
ameliorative	O
effects	O
.	O

Using	O
a	O
model	O
of	I:C0684309
experimental	I:C0684309
allergic	B:C0155877
asthma	I:C0155877
,	O
we	O
show	O
that	O
induction	O
of	O
IL	O
-	I:C1706289
27	I:C1706289
by	O
R848	O
is	O
critical	O
for	O
the	O
observed	O
ameliorative	O
effects	O
.	O

Using	O
a	O
model	O
of	I:C0684309
experimental	I:C0684309
allergic	O
asthma	I:C0155877
,	O
we	O
show	O
that	O
induction	B:C0857127
of	O
IL	O
-	I:C1706289
27	I:C1706289
by	O
R848	O
is	O
critical	O
for	O
the	O
observed	O
ameliorative	O
effects	O
.	O

Using	O
a	O
model	O
of	I:C0684309
experimental	I:C0684309
allergic	O
asthma	I:C0155877
,	O
we	O
show	O
that	O
induction	O
of	O
IL	B:C1706289
-	I:C1706289
27	I:C1706289
by	O
R848	O
is	O
critical	O
for	O
the	O
observed	O
ameliorative	O
effects	O
.	O

Using	O
a	O
model	O
of	I:C0684309
experimental	I:C0684309
allergic	O
asthma	I:C0155877
,	O
we	O
show	O
that	O
induction	O
of	O
IL	O
-	I:C1706289
27	I:C1706289
by	O
R848	B:C3642356
is	O
critical	O
for	O
the	O
observed	O
ameliorative	O
effects	O
.	O

R848	B:C3642356
significantly	O
inhibited	O
all	O
hallmarks	O
of	O
experimental	O
allergic	O
asthma	I:C0155877
,	O
including	O
airway	O
hyperreactivity	I:C0004096
,	O
eosinophilic	O
airway	O
inflammation	O
,	O
mucus	O
hypersecretion	I:C0155872
,	O
and	O
Ag	O
-	O
specific	O
Ig	I:C0358334
production	O
.	O

R848	O
significantly	O
inhibited	O
all	O
hallmarks	B:C1512330
of	O
experimental	O
allergic	O
asthma	I:C0155877
,	O
including	O
airway	O
hyperreactivity	I:C0004096
,	O
eosinophilic	O
airway	O
inflammation	O
,	O
mucus	O
hypersecretion	I:C0155872
,	O
and	O
Ag	O
-	O
specific	O
Ig	I:C0358334
production	O
.	O

R848	O
significantly	O
inhibited	O
all	O
hallmarks	O
of	O
experimental	O
allergic	B:C0155877
asthma	I:C0155877
,	O
including	O
airway	O
hyperreactivity	I:C0004096
,	O
eosinophilic	O
airway	O
inflammation	O
,	O
mucus	O
hypersecretion	I:C0155872
,	O
and	O
Ag	O
-	O
specific	O
Ig	I:C0358334
production	O
.	O

R848	O
significantly	O
inhibited	O
all	O
hallmarks	O
of	O
experimental	O
allergic	O
asthma	I:C0155877
,	O
including	O
airway	B:C0004096
hyperreactivity	I:C0004096
,	O
eosinophilic	O
airway	O
inflammation	O
,	O
mucus	O
hypersecretion	I:C0155872
,	O
and	O
Ag	O
-	O
specific	O
Ig	I:C0358334
production	O
.	O

R848	O
significantly	O
inhibited	O
all	O
hallmarks	O
of	O
experimental	O
allergic	O
asthma	I:C0155877
,	O
including	O
airway	O
hyperreactivity	I:C0004096
,	O
eosinophilic	O
airway	B:C0458827
inflammation	O
,	O
mucus	O
hypersecretion	I:C0155872
,	O
and	O
Ag	O
-	O
specific	O
Ig	I:C0358334
production	O
.	O

R848	O
significantly	O
inhibited	O
all	O
hallmarks	O
of	O
experimental	O
allergic	O
asthma	I:C0155877
,	O
including	O
airway	O
hyperreactivity	I:C0004096
,	O
eosinophilic	O
airway	O
inflammation	B:C0021368
,	O
mucus	O
hypersecretion	I:C0155872
,	O
and	O
Ag	O
-	O
specific	O
Ig	I:C0358334
production	O
.	O

R848	O
significantly	O
inhibited	O
all	O
hallmarks	O
of	O
experimental	O
allergic	O
asthma	I:C0155877
,	O
including	O
airway	O
hyperreactivity	I:C0004096
,	O
eosinophilic	O
airway	O
inflammation	O
,	O
mucus	B:C0155872
hypersecretion	I:C0155872
,	O
and	O
Ag	O
-	O
specific	O
Ig	I:C0358334
production	O
.	O

R848	O
significantly	O
inhibited	O
all	O
hallmarks	O
of	O
experimental	O
allergic	O
asthma	I:C0155877
,	O
including	O
airway	O
hyperreactivity	I:C0004096
,	O
eosinophilic	O
airway	O
inflammation	O
,	O
mucus	O
hypersecretion	I:C0155872
,	O
and	O
Ag	B:C0003320
-	O
specific	O
Ig	I:C0358334
production	O
.	O

R848	O
significantly	O
inhibited	O
all	O
hallmarks	O
of	O
experimental	O
allergic	O
asthma	I:C0155877
,	O
including	O
airway	O
hyperreactivity	I:C0004096
,	O
eosinophilic	O
airway	O
inflammation	O
,	O
mucus	O
hypersecretion	I:C0155872
,	O
and	O
Ag	O
-	O
specific	B:C0358334
Ig	I:C0358334
production	O
.	O

R848	O
significantly	O
inhibited	O
all	O
hallmarks	O
of	O
experimental	O
allergic	O
asthma	I:C0155877
,	O
including	O
airway	O
hyperreactivity	I:C0004096
,	O
eosinophilic	O
airway	O
inflammation	O
,	O
mucus	O
hypersecretion	I:C0155872
,	O
and	O
Ag	O
-	O
specific	O
Ig	I:C0358334
production	B:C0003261
.	O

Whereas	O
R848	B:C3642356
significantly	O
reduced	O
IL	O
-	I:C0021759
5	I:C0021759
,	O
IL	O
-	I:C0214743
13	I:C0214743
,	O
and	O
IL	O
-	I:C0384648
17	I:C0384648
,	O
it	O
induced	O
IFN	O
-γ	I:C3539881
and	O
IL	O
-	I:C1706289
27	I:C1706289
.	O

Whereas	O
R848	O
significantly	O
reduced	O
IL	B:C0021759
-	I:C0021759
5	I:C0021759
,	O
IL	O
-	I:C0214743
13	I:C0214743
,	O
and	O
IL	O
-	I:C0384648
17	I:C0384648
,	O
it	O
induced	O
IFN	O
-γ	I:C3539881
and	O
IL	O
-	I:C1706289
27	I:C1706289
.	O

Whereas	O
R848	O
significantly	O
reduced	O
IL	O
-	I:C0021759
5	I:C0021759
,	O
IL	B:C0214743
-	I:C0214743
13	I:C0214743
,	O
and	O
IL	O
-	I:C0384648
17	I:C0384648
,	O
it	O
induced	O
IFN	O
-γ	I:C3539881
and	O
IL	O
-	I:C1706289
27	I:C1706289
.	O

Whereas	O
R848	O
significantly	O
reduced	O
IL	O
-	I:C0021759
5	I:C0021759
,	O
IL	O
-	I:C0214743
13	I:C0214743
,	O
and	O
IL	B:C0384648
-	I:C0384648
17	I:C0384648
,	O
it	O
induced	O
IFN	O
-γ	I:C3539881
and	O
IL	O
-	I:C1706289
27	I:C1706289
.	O

Whereas	O
R848	O
significantly	O
reduced	O
IL	O
-	I:C0021759
5	I:C0021759
,	O
IL	O
-	I:C0214743
13	I:C0214743
,	O
and	O
IL	O
-	I:C0384648
17	I:C0384648
,	O
it	O
induced	O
IFN	B:C3539881
-γ	I:C3539881
and	O
IL	O
-	I:C1706289
27	I:C1706289
.	O

Whereas	O
R848	O
significantly	O
reduced	O
IL	O
-	I:C0021759
5	I:C0021759
,	O
IL	O
-	I:C0214743
13	I:C0214743
,	O
and	O
IL	O
-	I:C0384648
17	I:C0384648
,	O
it	O
induced	O
IFN	O
-γ	I:C3539881
and	O
IL	B:C1706289
-	I:C1706289
27	I:C1706289
.	O

Neutralization	O
of	O
IL	B:C1706289
-	I:C1706289
27	I:C1706289
completely	O
reversed	O
the	O
therapeutic	O
effect	I:C1527144
of	O
R848	O
in	O
the	O
experimental	O
asthma	O
model	O
,	O
demonstrating	O
dependence	O
of	O
R848	O
-	O
mediated	O
suppression	O
on	O
IL	O
-	I:C1706289
27	I:C1706289
.	O

Neutralization	O
of	O
IL	O
-	I:C1706289
27	I:C1706289
completely	O
reversed	O
the	O
therapeutic	B:C1527144
effect	I:C1527144
of	O
R848	O
in	O
the	O
experimental	O
asthma	O
model	O
,	O
demonstrating	O
dependence	O
of	O
R848	O
-	O
mediated	O
suppression	O
on	O
IL	O
-	I:C1706289
27	I:C1706289
.	O

Neutralization	O
of	O
IL	O
-	I:C1706289
27	I:C1706289
completely	O
reversed	O
the	O
therapeutic	O
effect	I:C1527144
of	O
R848	B:C3642356
in	O
the	O
experimental	O
asthma	O
model	O
,	O
demonstrating	O
dependence	O
of	O
R848	O
-	O
mediated	O
suppression	O
on	O
IL	O
-	I:C1706289
27	I:C1706289
.	O

Neutralization	O
of	O
IL	O
-	I:C1706289
27	I:C1706289
completely	O
reversed	O
the	O
therapeutic	O
effect	I:C1527144
of	O
R848	O
in	O
the	O
experimental	O
asthma	B:C0004096
model	O
,	O
demonstrating	O
dependence	O
of	O
R848	O
-	O
mediated	O
suppression	O
on	O
IL	O
-	I:C1706289
27	I:C1706289
.	O

Neutralization	O
of	O
IL	O
-	I:C1706289
27	I:C1706289
completely	O
reversed	O
the	O
therapeutic	O
effect	I:C1527144
of	O
R848	O
in	O
the	O
experimental	O
asthma	O
model	B:C0684309
,	O
demonstrating	O
dependence	O
of	O
R848	O
-	O
mediated	O
suppression	O
on	O
IL	O
-	I:C1706289
27	I:C1706289
.	O

Neutralization	O
of	O
IL	O
-	I:C1706289
27	I:C1706289
completely	O
reversed	O
the	O
therapeutic	O
effect	I:C1527144
of	O
R848	O
in	O
the	O
experimental	O
asthma	O
model	O
,	O
demonstrating	O
dependence	O
of	O
R848	B:C3642356
-	O
mediated	O
suppression	O
on	O
IL	O
-	I:C1706289
27	I:C1706289
.	O

Neutralization	O
of	O
IL	O
-	I:C1706289
27	I:C1706289
completely	O
reversed	O
the	O
therapeutic	O
effect	I:C1527144
of	O
R848	O
in	O
the	O
experimental	O
asthma	O
model	O
,	O
demonstrating	O
dependence	O
of	O
R848	O
-	O
mediated	O
suppression	B:C0021079
on	O
IL	O
-	I:C1706289
27	I:C1706289
.	O

Neutralization	O
of	O
IL	O
-	I:C1706289
27	I:C1706289
completely	O
reversed	O
the	O
therapeutic	O
effect	I:C1527144
of	O
R848	O
in	O
the	O
experimental	O
asthma	O
model	O
,	O
demonstrating	O
dependence	O
of	O
R848	O
-	O
mediated	O
suppression	O
on	O
IL	B:C1706289
-	I:C1706289
27	I:C1706289
.	O

In	O
vitro	O
,	O
R848	B:C3642356
induced	O
production	O
of	O
IL	O
-	I:C1706289
27	I:C1706289
by	O
murine	O
alveolar	O
macrophages	I:C0085236
and	O
dendritic	O
cells	I:C0011306
and	O
enhanced	O
expression	O
of	O
programmed	O
death	O
-	O
ligand	O
1	O
,	O
whose	O
expression	O
on	O
monocytes	O
and	O
dendritic	O
cells	I:C0011306
has	O
been	O
shown	O
to	O
regulate	O
peripheral	O
tolerance	I:C3179073
in	O
both	O
murine	O
and	O
human	O
studies	O
.	O

In	O
vitro	O
,	O
R848	O
induced	B:C0857127
production	O
of	O
IL	O
-	I:C1706289
27	I:C1706289
by	O
murine	O
alveolar	O
macrophages	I:C0085236
and	O
dendritic	O
cells	I:C0011306
and	O
enhanced	O
expression	O
of	O
programmed	O
death	O
-	O
ligand	O
1	O
,	O
whose	O
expression	O
on	O
monocytes	O
and	O
dendritic	O
cells	I:C0011306
has	O
been	O
shown	O
to	O
regulate	O
peripheral	O
tolerance	I:C3179073
in	O
both	O
murine	O
and	O
human	O
studies	O
.	O

In	O
vitro	O
,	O
R848	O
induced	O
production	O
of	O
IL	B:C1706289
-	I:C1706289
27	I:C1706289
by	O
murine	O
alveolar	O
macrophages	I:C0085236
and	O
dendritic	O
cells	I:C0011306
and	O
enhanced	O
expression	O
of	O
programmed	O
death	O
-	O
ligand	O
1	O
,	O
whose	O
expression	O
on	O
monocytes	O
and	O
dendritic	O
cells	I:C0011306
has	O
been	O
shown	O
to	O
regulate	O
peripheral	O
tolerance	I:C3179073
in	O
both	O
murine	O
and	O
human	O
studies	O
.	O

In	O
vitro	O
,	O
R848	O
induced	O
production	O
of	O
IL	O
-	I:C1706289
27	I:C1706289
by	O
murine	B:C0026809
alveolar	O
macrophages	I:C0085236
and	O
dendritic	O
cells	I:C0011306
and	O
enhanced	O
expression	O
of	O
programmed	O
death	O
-	O
ligand	O
1	O
,	O
whose	O
expression	O
on	O
monocytes	O
and	O
dendritic	O
cells	I:C0011306
has	O
been	O
shown	O
to	O
regulate	O
peripheral	O
tolerance	I:C3179073
in	O
both	O
murine	O
and	O
human	O
studies	O
.	O

In	O
vitro	O
,	O
R848	O
induced	O
production	O
of	O
IL	O
-	I:C1706289
27	I:C1706289
by	O
murine	O
alveolar	B:C0085236
macrophages	I:C0085236
and	O
dendritic	O
cells	I:C0011306
and	O
enhanced	O
expression	O
of	O
programmed	O
death	O
-	O
ligand	O
1	O
,	O
whose	O
expression	O
on	O
monocytes	O
and	O
dendritic	O
cells	I:C0011306
has	O
been	O
shown	O
to	O
regulate	O
peripheral	O
tolerance	I:C3179073
in	O
both	O
murine	O
and	O
human	O
studies	O
.	O

In	O
vitro	O
,	O
R848	O
induced	O
production	O
of	O
IL	O
-	I:C1706289
27	I:C1706289
by	O
murine	O
alveolar	O
macrophages	I:C0085236
and	O
dendritic	B:C0011306
cells	I:C0011306
and	O
enhanced	O
expression	O
of	O
programmed	O
death	O
-	O
ligand	O
1	O
,	O
whose	O
expression	O
on	O
monocytes	O
and	O
dendritic	O
cells	I:C0011306
has	O
been	O
shown	O
to	O
regulate	O
peripheral	O
tolerance	I:C3179073
in	O
both	O
murine	O
and	O
human	O
studies	O
.	O

In	O
vitro	O
,	O
R848	O
induced	O
production	O
of	O
IL	O
-	I:C1706289
27	I:C1706289
by	O
murine	O
alveolar	O
macrophages	I:C0085236
and	O
dendritic	O
cells	I:C0011306
and	O
enhanced	O
expression	B:C1171362
of	O
programmed	O
death	O
-	O
ligand	O
1	O
,	O
whose	O
expression	O
on	O
monocytes	O
and	O
dendritic	O
cells	I:C0011306
has	O
been	O
shown	O
to	O
regulate	O
peripheral	O
tolerance	I:C3179073
in	O
both	O
murine	O
and	O
human	O
studies	O
.	O

In	O
vitro	O
,	O
R848	O
induced	O
production	O
of	O
IL	O
-	I:C1706289
27	I:C1706289
by	O
murine	O
alveolar	O
macrophages	I:C0085236
and	O
dendritic	O
cells	I:C0011306
and	O
enhanced	O
expression	O
of	O
programmed	O
death	O
-	O
ligand	O
1	O
,	O
whose	O
expression	B:C1171362
on	O
monocytes	O
and	O
dendritic	O
cells	I:C0011306
has	O
been	O
shown	O
to	O
regulate	O
peripheral	O
tolerance	I:C3179073
in	O
both	O
murine	O
and	O
human	O
studies	O
.	O

In	O
vitro	O
,	O
R848	O
induced	O
production	O
of	O
IL	O
-	I:C1706289
27	I:C1706289
by	O
murine	O
alveolar	O
macrophages	I:C0085236
and	O
dendritic	O
cells	I:C0011306
and	O
enhanced	O
expression	O
of	O
programmed	O
death	O
-	O
ligand	O
1	O
,	O
whose	O
expression	O
on	O
monocytes	B:C0085236
and	O
dendritic	O
cells	I:C0011306
has	O
been	O
shown	O
to	O
regulate	O
peripheral	O
tolerance	I:C3179073
in	O
both	O
murine	O
and	O
human	O
studies	O
.	O

In	O
vitro	O
,	O
R848	O
induced	O
production	O
of	O
IL	O
-	I:C1706289
27	I:C1706289
by	O
murine	O
alveolar	O
macrophages	I:C0085236
and	O
dendritic	O
cells	I:C0011306
and	O
enhanced	O
expression	O
of	O
programmed	O
death	O
-	O
ligand	O
1	O
,	O
whose	O
expression	O
on	O
monocytes	O
and	O
dendritic	B:C0011306
cells	I:C0011306
has	O
been	O
shown	O
to	O
regulate	O
peripheral	O
tolerance	I:C3179073
in	O
both	O
murine	O
and	O
human	O
studies	O
.	O

In	O
vitro	O
,	O
R848	O
induced	O
production	O
of	O
IL	O
-	I:C1706289
27	I:C1706289
by	O
murine	O
alveolar	O
macrophages	I:C0085236
and	O
dendritic	O
cells	I:C0011306
and	O
enhanced	O
expression	O
of	O
programmed	O
death	O
-	O
ligand	O
1	O
,	O
whose	O
expression	O
on	O
monocytes	O
and	O
dendritic	O
cells	I:C0011306
has	O
been	O
shown	O
to	O
regulate	B:C1327622
peripheral	O
tolerance	I:C3179073
in	O
both	O
murine	O
and	O
human	O
studies	O
.	O

In	O
vitro	O
,	O
R848	O
induced	O
production	O
of	O
IL	O
-	I:C1706289
27	I:C1706289
by	O
murine	O
alveolar	O
macrophages	I:C0085236
and	O
dendritic	O
cells	I:C0011306
and	O
enhanced	O
expression	O
of	O
programmed	O
death	O
-	O
ligand	O
1	O
,	O
whose	O
expression	O
on	O
monocytes	O
and	O
dendritic	O
cells	I:C0011306
has	O
been	O
shown	O
to	O
regulate	O
peripheral	B:C3179073
tolerance	I:C3179073
in	O
both	O
murine	O
and	O
human	O
studies	O
.	O

In	O
vitro	O
,	O
R848	O
induced	O
production	O
of	O
IL	O
-	I:C1706289
27	I:C1706289
by	O
murine	O
alveolar	O
macrophages	I:C0085236
and	O
dendritic	O
cells	I:C0011306
and	O
enhanced	O
expression	O
of	O
programmed	O
death	O
-	O
ligand	O
1	O
,	O
whose	O
expression	O
on	O
monocytes	O
and	O
dendritic	O
cells	I:C0011306
has	O
been	O
shown	O
to	O
regulate	O
peripheral	O
tolerance	I:C3179073
in	O
both	O
murine	B:C0026809
and	O
human	O
studies	O
.	O

In	O
vitro	O
,	O
R848	O
induced	O
production	O
of	O
IL	O
-	I:C1706289
27	I:C1706289
by	O
murine	O
alveolar	O
macrophages	I:C0085236
and	O
dendritic	O
cells	I:C0011306
and	O
enhanced	O
expression	O
of	O
programmed	O
death	O
-	O
ligand	O
1	O
,	O
whose	O
expression	O
on	O
monocytes	O
and	O
dendritic	O
cells	I:C0011306
has	O
been	O
shown	O
to	O
regulate	O
peripheral	O
tolerance	I:C3179073
in	O
both	O
murine	O
and	O
human	B:C0086418
studies	O
.	O

Moreover	O
,	O
in	O
vitro	O
IL	B:C1706289
-	I:C1706289
27	I:C1706289
enhanced	O
secretion	O
of	O
IFN	O
-γ	I:C3539881
whereas	O
it	O
inhibited	O
IL	O
-	I:C0021759
5	I:C0021759
and	O
IL	O
-	I:C0214743
13	I:C0214743
,	O
demonstrating	O
its	O
direct	O
effect	O
on	O
attenuating	O
Th2	O
responses	O
.	O

Moreover	O
,	O
in	O
vitro	O
IL	O
-	I:C1706289
27	I:C1706289
enhanced	O
secretion	B:C1327616
of	O
IFN	O
-γ	I:C3539881
whereas	O
it	O
inhibited	O
IL	O
-	I:C0021759
5	I:C0021759
and	O
IL	O
-	I:C0214743
13	I:C0214743
,	O
demonstrating	O
its	O
direct	O
effect	O
on	O
attenuating	O
Th2	O
responses	O
.	O

Moreover	O
,	O
in	O
vitro	O
IL	O
-	I:C1706289
27	I:C1706289
enhanced	O
secretion	O
of	O
IFN	B:C3539881
-γ	I:C3539881
whereas	O
it	O
inhibited	O
IL	O
-	I:C0021759
5	I:C0021759
and	O
IL	O
-	I:C0214743
13	I:C0214743
,	O
demonstrating	O
its	O
direct	O
effect	O
on	O
attenuating	O
Th2	O
responses	O
.	O

Moreover	O
,	O
in	O
vitro	O
IL	O
-	I:C1706289
27	I:C1706289
enhanced	O
secretion	O
of	O
IFN	O
-γ	I:C3539881
whereas	O
it	O
inhibited	O
IL	B:C0021759
-	I:C0021759
5	I:C0021759
and	O
IL	O
-	I:C0214743
13	I:C0214743
,	O
demonstrating	O
its	O
direct	O
effect	O
on	O
attenuating	O
Th2	O
responses	O
.	O

Moreover	O
,	O
in	O
vitro	O
IL	O
-	I:C1706289
27	I:C1706289
enhanced	O
secretion	O
of	O
IFN	O
-γ	I:C3539881
whereas	O
it	O
inhibited	O
IL	O
-	I:C0021759
5	I:C0021759
and	O
IL	B:C0214743
-	I:C0214743
13	I:C0214743
,	O
demonstrating	O
its	O
direct	O
effect	O
on	O
attenuating	O
Th2	O
responses	O
.	O

Moreover	O
,	O
in	O
vitro	O
IL	O
-	I:C1706289
27	I:C1706289
enhanced	O
secretion	O
of	O
IFN	O
-γ	I:C3539881
whereas	O
it	O
inhibited	O
IL	O
-	I:C0021759
5	I:C0021759
and	O
IL	O
-	I:C0214743
13	I:C0214743
,	O
demonstrating	O
its	O
direct	O
effect	O
on	O
attenuating	O
Th2	B:C0242633
responses	O
.	O

Taken	O
together	O
,	O
our	O
study	O
proves	O
that	O
R848	B:C3642356
-	O
mediated	O
suppression	O
of	O
experimental	O
asthma	O
is	O
dependent	O
on	O
IL	O
-	I:C1706289
27	I:C1706289
.	O

Taken	O
together	O
,	O
our	O
study	O
proves	O
that	O
R848	O
-	O
mediated	O
suppression	B:C0021079
of	O
experimental	O
asthma	O
is	O
dependent	O
on	O
IL	O
-	I:C1706289
27	I:C1706289
.	O

Taken	O
together	O
,	O
our	O
study	O
proves	O
that	O
R848	O
-	O
mediated	O
suppression	O
of	O
experimental	O
asthma	B:C0004096
is	O
dependent	O
on	O
IL	O
-	I:C1706289
27	I:C1706289
.	O

Taken	O
together	O
,	O
our	O
study	O
proves	O
that	O
R848	O
-	O
mediated	O
suppression	O
of	O
experimental	O
asthma	O
is	O
dependent	O
on	O
IL	B:C1706289
-	I:C1706289
27	I:C1706289
.	O

These	O
data	O
provide	O
evidence	O
of	O
a	O
central	O
role	O
of	O
IL	B:C1706289
-	I:C1706289
27	I:C1706289
for	O
the	O
control	O
of	O
Th2	O
-	O
mediated	O
allergic	O
diseases	I:C1504369
.	O

These	O
data	O
provide	O
evidence	O
of	O
a	O
central	O
role	O
of	O
IL	O
-	I:C1706289
27	I:C1706289
for	O
the	O
control	O
of	O
Th2	B:C0242633
-	O
mediated	O
allergic	O
diseases	I:C1504369
.	O

These	O
data	O
provide	O
evidence	O
of	O
a	O
central	O
role	O
of	O
IL	O
-	I:C1706289
27	I:C1706289
for	O
the	O
control	O
of	O
Th2	O
-	O
mediated	O
allergic	B:C1504369
diseases	I:C1504369
.	O

